Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,543.14 26.87 0.19%
TOPIX 1,173.12 -0.25 -0.02%
HANG SENG 22,760.24 64.23 0.28%

North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55 Billion by 2017



   North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55
                               Billion by 2017

  PR Newswire

  DALLAS, April 10, 2013

DALLAS, April 10, 2013 /PRNewswire/ --

The  " North American Nuclear Medicine/Radiopharmaceuticals Market   & Stable
Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation
Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium,
C-13)   -   Forecast to 2017"  analyzes and studies the major market drivers,
restraints, and opportunities in North America, Latin America, Europe, Asia,
and Rest of the World.

Browse

  * 120  market data tables
  * 29  figures
  * 280  pages and an in-depth Table of Content on "North American Nuclear
    Medicine / Radiopharmaceutical Market"

http://www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html

Early buyers will receive 10% customization on this report.

This report studies the North American nuclear medicine market over the
forecast period 2012-2017.

The North American radiopharmaceutical market was valued at $1.9 billion in
2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%. It is
estimated that Tc-99m diagnostic procedures are expected to increase by more
than 15% in mature markets such as North America, between 2010 and 2030,
however shortage of Mo-99/Tc-99m has been a threat to this industry. The
scheduled shutdown of the NRU reactor in 2016 is a major risk for
manufacturers in the near future. Companies have increased the production of
thallium to meet the shortage, as it is the most commonly used substitute for
technetium-99 in cardiac-stress tests, conducted to evaluate the functioning
of coronary arteries. Radiopharmaceuticals in neurological applications such
as Alzheimer's disease, Parkinson's disease, and dementia are also being
preferred by practitioners besides conventional treatment. Further, upcoming
radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for
clinical applications.

Increasing use of SPECT and PET scans, technical advancements in equipment and
other factors such as rising awareness of radiopharmaceuticals among
physicians, alpha radio immunotherapy based targeted cancer treatment, and
ready availability of north american nuclear medicine / radiopharmaceutical
market from cyclotrons have driven the market. High cost of devices using
radioisotopes, short half-life, lack of good manufacturing practices, and
stringent regulatory approvals are major hurdles to growth of the market.

North America is the dominant market for diagnostic radioisotopes. The U.S. is
the largest consumer market for radiopharmaceuticals, while Canada is one of
the largest producers of Tc-99m.

Major players in the radiopharmaceuticals market are Cardinal Health, Inc.
(U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and
Triad Isotopes, Inc. (U.S.), Cardinal Health dominated with more than 40%
share in 2012.

The stable isotopes market was less than $50 million in 2012 and poised to
grow at high double digit CAGR in the next 5 years. Carbon-13 commanded the
largest share of the global stable isotope market in 2012; however deuterium
and oxygen show tremendous potential to grow in the near future. The market
was dominated by two players, Cambridge Isotope Laboratories (CIL) (U.S.) and
Isotec (Sigma Aldrich) (U.S.) in 2012 jointly contributing more than 90% to
the North America revenue.

Buy a copy of this report @
http://www.marketsandmarkets.com/Purchase/purchase_report1.asp?id=1108

Browse related reports to P harmaceutical   Market @
http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in
the U.S. We publish strategically analyzed market research reports and serve
as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles,
databases, and custom research services. MarketsandMarkets covers thirteen
industry verticals; including advanced materials, automotives and
transportation, banking and financial services, biotechnology, chemicals,
consumer goods, telecommunications and IT, energy and power, food and
beverages, industrial automation, medical devices, pharmaceuticals
, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt
business insight with our huge market intelligence repository.

Contact:

Mr. Rohan North - Dominion Plaza 17304 Preston Road Suite 800, Dallas,
TX 75252 Tel: +1-888-6006-441 Email:  sales@marketsandmarkets.com

Visit MarketsandMarkets Blog @  http://www.marketsandmarketsblog.com

Connect with us on LinkedIn @ 
http://www.linkedin.com/company/marketsandmarkets
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement